| scholarly article | Q13442814 |
| P2093 | author name string | F Valafar | |
| H Valafar | |||
| L C Morris | |||
| R Cherniak | |||
| P2860 | cites work | Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. | Q30424017 |
| Application of neural networks to the interpretation of laboratory data in cancer diagnosis | Q31104290 | ||
| Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness | Q34420549 | ||
| Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. | Q35390183 | ||
| Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay. | Q35409786 | ||
| The application of backpropagation neural networks to problems in pathology and laboratory medicine | Q35449453 | ||
| Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells | Q35534083 | ||
| Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. | Q35567548 | ||
| Serotyping of Cryptococcus neoformans by dot enzyme assay. | Q36527966 | ||
| Cryptococcus neoformans. 3. Inhibition of phagocytosis. | Q36845787 | ||
| The Ecology of Cryptococcus neoformans and the Epidemiology of Cryptococcosis | Q36924047 | ||
| Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans | Q36958708 | ||
| Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). | Q37290596 | ||
| Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates | Q37294739 | ||
| Polysaccharide antigens of the capsule of Cryptococcus neoformans | Q39859915 | ||
| Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans | Q39860295 | ||
| Capsular Polysaccharides of Cryptococcus neoformans | Q40112336 | ||
| Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus | Q40938412 | ||
| Cryptococcal infection in AIDS. | Q44645052 | ||
| Analysis of the secondary structure of the human immunodeficiency virus (HIV) proteins p17, gp120, and gp41 by computer modeling based on neural network methods. | Q45850354 | ||
| The antigenic composition of Cryptococcus neoformans. I. A serologic classification by means of the capsular and agglutination reactions | Q47975634 | ||
| Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. | Q48217239 | ||
| Unsupervised learning and discriminant analysis applied to identification of high risk postoperative cardiac patients. | Q52241757 | ||
| Parallel, self-organizing, hierarchical neural networks. | Q52242607 | ||
| Sulfate detection in glycoprotein-derived oligosaccharides by artificial neural network analysis of Fourier-transform infrared spectra. | Q52374751 | ||
| Neural network-based recognition of oligosaccharide 1H-NMR spectra. | Q52379561 | ||
| Noninvasive diagnosis of coronary artery disease using a neural network algorithm | Q52432158 | ||
| Identification of the 1H-NMR spectra of complex oligosaccharides with artificial neural networks. | Q52456869 | ||
| Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans | Q58663623 | ||
| Structural variability in the glucuronoxylomannan of Cryptococcus neoformans serotype A isolates determined by 13C NMR spectroscopy | Q67589353 | ||
| Complete assignment of the 1H- and 13C-n.m.r. spectra of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans serotype B | Q67889821 | ||
| Applications of neural networks in quantitative structure-activity relationships of dihydrofolate reductase inhibitors | Q67977559 | ||
| Cryptococcal meningitis in patients with AIDS | Q68128522 | ||
| Serogroup distribution of Cryptococcus neoformans in patients with AIDS | Q68162790 | ||
| Glucuronoxylomannan of Cryptococcus neoformans serotype C: structural analysis by gas-liquid chromatography-mass spectrometry and 13C-nuclear magnetic resonance spectroscopy | Q68234219 | ||
| Potential usefulness of an artificial neural network for differential diagnosis of interstitial lung diseases: pilot study | Q68608790 | ||
| Serotypes of Cryptococcus neoformans in patients with AIDS | Q68861781 | ||
| The variety of Cryptococcus neoformans in patients with AIDS | Q68917658 | ||
| Cryptococcosis in the acquired immunodeficiency syndrome | Q69907540 | ||
| The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages | Q70254971 | ||
| Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans serotype C as determined by 2D 1H NMR spectroscopy | Q70840109 | ||
| Decreased virulence in stable, acapsular mutants of cryptococcus neoformans | Q71441160 | ||
| Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans Cap70 as determined by 2D NMR spectroscopy | Q71744863 | ||
| Enhancement of HIV-1 replication in peripheral blood mononuclear cells by Cryptococcus neoformans is monocyte-dependent but tumour necrosis factor-independent | Q72014702 | ||
| Serologic Grouping of Cryptococcus neoformans | Q72047391 | ||
| A neural model of cortical map reorganization following a focal lesion | Q72501096 | ||
| Glucuronoxylomannan of Cryptococcus neoformans obtained from patients with AIDS | Q72692144 | ||
| Structural analysis of the carbohydrate chains of mucin-type glycoproteins by high-resolution 1H-n.m.r. spectroscopy | Q72747743 | ||
| Structure of the 13C-enriched O-deacetylated glucuronoxylomannan of Cryptococcus neoformans serotype A determined by NMR spectroscopy | Q73522391 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | artificial neural network | Q192776 |
| Cryptococcus neoformans | Q131924 | ||
| P304 | page(s) | 146-159 | |
| P577 | publication date | 1998-03-01 | |
| P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
| P1476 | title | Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network | |
| P478 | volume | 5 |
| Q38290090 | A Monoclonal Antibody to Cryptococcus neoformans Glucuronoxylomannan Manifests Hydrolytic Activity for Both Peptides and Polysaccharides. |
| Q28538344 | A role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsule |
| Q39497278 | A unique alpha-1,3 mannosyltransferase of the pathogenic fungus Cryptococcus neoformans. |
| Q35128286 | A xylosylphosphotransferase of Cryptococcus neoformans acts in protein O-glycan synthesis. |
| Q35197202 | A yeast under cover: the capsule of Cryptococcus neoformans |
| Q36950154 | Allergen1 regulates polysaccharide structure in Cryptococcus neoformans |
| Q39746326 | Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains |
| Q34301177 | Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages |
| Q41938980 | Biosynthesis of UDP-GlcA, a key metabolite for capsular polysaccharide synthesis in the pathogenic fungus Cryptococcus neoformans |
| Q37982326 | Capsular Material of Cryptococcus neoformans: Virulence and Much More. |
| Q35011899 | Capsular polysaccharides from Cryptococcus neoformans modulate production of neutrophil extracellular traps (NETs) by human neutrophils |
| Q37078933 | Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules |
| Q41780353 | Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans |
| Q28478860 | Capsules from pathogenic and non-pathogenic Cryptococcus spp. manifest significant differences in structure and ability to protect against phagocytic cells |
| Q33560210 | Cas3p belongs to a seven-member family of capsule structure designer proteins |
| Q35598044 | Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans |
| Q40622604 | Circular Dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure |
| Q36642384 | Comparative hybridization reveals extensive genome variation in the AIDS-associated pathogen Cryptococcus neoformans |
| Q34779166 | Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan |
| Q37189868 | Contribution of murine IgG Fc regions to antibody binding to the capsule of Burkholderia pseudomallei |
| Q56783128 | Cryptococcal Traits Mediating Adherence to Biotic and Abiotic Surfaces |
| Q36662728 | Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides |
| Q40586172 | Cryptococcus neoformans UGT1 encodes a UDP-Galactose/UDP-GalNAc transporter. |
| Q33790656 | Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis |
| Q43029434 | Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences |
| Q34146274 | Cryptococcus neoformans capsule structure evolution in vitro and during murine infection |
| Q33743564 | Cryptococcus neoformans dual GDP-mannose transporters and their role in biology and virulence. |
| Q34005219 | Cryptococcus neoformans hyperfilamentous strain is hypervirulent in a murine model of cryptococcal meningoencephalitis |
| Q36154961 | Cryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella |
| Q33939999 | Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo. |
| Q58798947 | Dectin-3 Recognizes Glucuronoxylomannan of Serotype AD and Serotype B to Initiate Host Defense Against Cryptococcosis |
| Q34681238 | Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans |
| Q35291602 | Emerging themes in cryptococcal capsule synthesis |
| Q36431950 | Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure |
| Q34561087 | Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. |
| Q89473482 | Exploring Cryptococcus neoformans capsule structure and assembly with a hydroxylamine-armed fluorescent probe |
| Q34123230 | Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity |
| Q37187211 | Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans |
| Q33946946 | Functional cloning and characterization of a UDP- glucuronic acid decarboxylase: the pathogenic fungus Cryptococcus neoformans elucidates UDP-xylose synthesis |
| Q42722736 | Glucuronoxylomannan from Cryptococcus neoformans down-regulates the enzyme 6-phosphofructo-1-kinase of macrophages. |
| Q33894565 | How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans |
| Q34780084 | Immunoreactivity of cryptococcal antigen is not stable under prolonged incubations in human serum |
| Q34001243 | In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies |
| Q37355720 | Lipophilic dye staining of Cryptococcus neoformans extracellular vesicles and capsule |
| Q49410181 | Masking the Pathogen: Evolutionary Strategies of Fungi and Their Bacterial Counterparts. |
| Q36704709 | Microreview: capsule-associated genes of Cryptococcus neoformans |
| Q35923662 | Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans |
| Q35138768 | Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen |
| Q35197055 | Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformans |
| Q73936271 | Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors |
| Q33766799 | Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly. |
| Q55056045 | Peeling the onion: the outer layers of Cryptococcus neoformans. |
| Q37600634 | Phenotypic Switching in Fungi |
| Q64098520 | Phenotypic characteristics and transcriptome profile of Cryptococcus gattii biofilm |
| Q37459771 | Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule |
| Q36476671 | Phenotypic switching and its implications for the pathogenesis of Cryptococcus neoformans |
| Q82130569 | Phenotypic switching in Cryptococcus neoformans |
| Q39512897 | Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure |
| Q34334384 | Phenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system |
| Q41870667 | Production of extracellular polysaccharides by CAP mutants of Cryptococcus neoformans |
| Q33188024 | Rapid identification of Candida species by using nuclear magnetic resonance spectroscopy and a statistical classification strategy |
| Q30479935 | Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations |
| Q39873096 | Structural and functional properties of the Trichosporon asahii glucuronoxylomannan |
| Q30555314 | Temporal behavior of capsule enlargement by Cryptococcus neoformans |
| Q50046707 | The Capsule of Cryptococcus neoformans. |
| Q37337879 | The capsule of the fungal pathogen Cryptococcus neoformans |
| Q34099803 | The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies |
| Q37303951 | The elastic properties of the Cryptococcus neoformans capsule |
| Q42738532 | The pathogenic fungus Cryptococcus neoformans expresses two functional GDP-mannose transporters with distinct expression patterns and roles in capsule synthesis |
| Q41520565 | The structure of Cryptococcus neoformans galactoxylomannan contains beta-D-glucuronic acid |
| Q47830888 | UDP-Glucuronic Acid Transport Is Required for Virulence of Cryptococcus neoformans. |
| Q52323839 | Unraveling synthesis of the cryptococcal cell wall and capsule. |
| Q36779547 | Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast Cryptococcus neoformans. |
| Q35583106 | Variable Region Identical IgA and IgE to Cryptococcus neoformans Capsular Polysaccharide Manifest Specificity Differences. |
| Q94461356 | Variation in Cell Surface Hydrophobicity among Cryptococcus neoformans Strains Influences Interactions with Amoebas |
| Q48218058 | Xylose donor transport is critical for fungal virulence |
Search more.